The Metabolic Syndrome And Specific Populations At Risk: Can Precision And Individualized Medicine Change Things?

Abstract

Objectives of the study: the metabolic syndrome (MS) consists of a group of metabolic alterations that have insulin resistance as their common denominator and identifies a pathophysiological condition at high risk of developing cardiovascular disease and type 2 diabetes. 20% and 30% of the adult population is affected by MS Design and method: in this article the authors try to make a scientific contribution regarding the problems of some patient populations often having to necessarily take drugs with an important metabolic impact while developing an iatrogenic-based MS (IMS) and propose to further investigate the aspects and the clinical pharmacological problems of the population of psychiatric patients at risk of MS. Results: Although the prevalence of MS has been observed to be often higher in the urban population of some developing countries, there are patient populations who develop MS due to the extensive use of certain drugs with obesogenic-metabolic adverse effects, in particular some generations of antidepressant and neuroleptic drugs (NL) used in mental disorders and antiretroviral drugs, such as integrase inhibitors used in HIV infection. Conclusions: Populations at risk of IMS should be at the center of the search for an individualized precision medicine with the careful choice of pharmacological therapies and appropriate lifestyle. Unfortunately, precision medicine in the psychiatric field seems to be stopping its growth due to the lack of identification of biomarkers and indicators of psychopathology.